To view this email as a web page, click here

   Home

Subscribe

Advertise

 

 

 

 

September 06, 2019___

Today's Rundown

Featured Story

Roivant lines up $3B upfront in Sumitomo Dainippon deal 

Sumitomo Dainippon is set to pay $3 billion upfront to buy Roivant’s stake in five of its Vant startups. The deal could provide Dainippon with a series of new product launches to offset the loss of patent protection on bipolar depression drug Latuda.

Top Stories

Zealand CSO steps up as chief of French biotech

At the end of July, Zealand Pharma’s chief scientific officer Andrew Parker, Ph.D., hit the exit, off to an unknown biotech. Today, we know where he landed: as CEO of Step Pharma.

Zafgen hangs 'for sale' sign as chances of imminent recovery fade

Zafgen has begun looking for someone to rescue it from its sticky predicament. The biotech put out the call for a strategic alternatives after preliminary data from an animal study suggested it is unlikely to get ZGN-1061 out from under a FDA clinical in the near term.

Opthea’s Lucentis/VEGF ‘trap’ combo outshines Lucentis alone in wet AMD

Opthea tested two doses of its drug, OPT-302, in combination with Lucentis, finding that the combo bested Lucentis alone at improving vision and reducing scarring in the retina. The Australian company is now gearing up for a phase 3 study.

Applying 'rock-paper-scissors' gene circuits to cancer therapy

By cycling through three strains of bacteria, bioengineers at the University of California San Diego developed a “rock-paper-scissors” method to prolong the function of gene circuits that can be used to produce and deliver cancer drugs.

EuroBiotech Report—Achilles raises $100M, MGB round, Genfit CEO change and AstraZeneca

In this week's EuroBiotech Report, Achilles raises $100 million, MGB tops up cash reserves and Genfit unveils CEO transition.

FiercePharmaAsia—Biocon, Mylan’s Lantus copy CRL; CStone CEO pay; Novartis’ site sale

Mylan's Lantus copy was rejected by the FDA again, thanks to partner Biocon's manufacturing shortfalls. Chinese biotech CStone's CEO made nearly $20 million in pay last year, putting him on par with Merck & Co.'s CEO. Novartis will sell its Suzhou, China plant for $111 million. And more.

Chutes & Ladders—Bausch Health's Salix loses McKenna to Prometheus

Bausch Health's Salix loses president Mark McKenna; Bayer nabs dealmaker Marianne De Backer from J&J; AltaSciences nabs Charles River exec Lynne LeSauteur.

Enrollment Showcase

BioImmersion: Biotech for the Non-Scientist

BioImmersion: Biotech for the Non-Scientist is a three-day, in-depth course that delves into the scientific details on a broad number of biotechnology topics. Register today!

Resources

[Whitepaper] How Can You Avoid the Fallout From Incompatibility Between Your API and Its Formulation?

Avoid potential risks to the patient as well as costly interruptions during development.

[Whitepaper] From Complex to Controlled: Advanced Data Management Strategies for Advanced Therapies

Developing a cell therapy, gene therapy, or personalized cancer vaccine? Modern data management makes a critical difference in operational and regulatory outcomes. This whitepaper will help your team leverage the latest data strategies for success.

[Whitepaper] Advancing Healthcare Market Intelligence With Smart Search Technology

AI-powered research tools are making it easier to source confident healthcare market intelligence with accuracy and efficiency -- download now to learn more about improving your competitive research strategy.

[Whitepaper] What's Your Lab Trying to Tell You? Listen with Connected IoT Sensors

Your lab is talking to you, are you listening?

[Whitepaper] Prevent the Real World From Derailing Your Clinical Trial: Focus on Protocol Design

Want to be sure your renal research protocol design is fit for the real world?

[Whitepaper] Optimizing Operations in Multiproduct Pharma Manufacturing Facilities

Vetting CDMOs but unsure what to look for in prospective partners’ multiproduct facilities?

[Report] Future of clinical trials: From real-time data to algorithmic trials

Clinical trials are one of the pharma industry’s most painful and costly processes. Read how technology could transform the trial process from nine years to a matter of hours.

[Whitepaper] Considerations and Options for Prefilled Syringes

Check out Baxter BioPharma Solutions’ whitepaper to learn considerations and options for developing a product in a prefilled syringe.

[Article] Sales Compensation: 7 Trending Topics

From sales headcount and budgets to new product launches and saying “yes” to millennials, hear the top 7 topics that are trending in sales compensation.

[Whitepaper] Enhancing Productivity in Drug Discovery: Removing Inefficiencies and Distractions Caused by Chemicals and Biologics Management

The regulations and managing processes for hazardous, controlled and rare chemicals and biologics necessary for drug discovery are a huge distraction for R&D labs. Learn from the perspectives of industry executives the pain points and improvements they want in their processes for chemicals and biologics in pharmaceuticals R&D.

[Whitepaper] The Supply Chain Planning Cure for Everything from Product Expirations to Patent Cliffs

Download this life sciences industry spotlight to discover how concurrent planning can help you overcome complex supply chain challenges to drive down costs and improve efficiency.

[Case Study] Clinical Supply Management

Download the case study to learn about the clinical supply management tools that helped a small sized pharma company during phase III of a multi-arm oncology study.

[Video] Demand Led Services and Clinical Supply Efficiency

Watch a short video on demand led supply model. It is designed to meet the needs of patients, clinical sites, clinical team and sponsors and results in shorter lead time, less waste, less stock out risk and no booklet labels.

[eBook] Strategies for Efficient Clinical Supply Management and Forecasting

Download the eBook to explore a proactive approach for clinical supply management.

Events